TEENs Study Shows Achieving Target Blood Sugar Levels is Associated with Better Quality of Life for Young People with Type 1 Diabetes

Paris (ots/PRNewswire) -

- Findings set foundation to drive recommendations for enhancing
care -

Sanofi announced today the first results of the TEENs Registry
Study, the largest contemporary real-world study of the care of
nearly 6,000 young people with type 1 diabetes, ages 8 to 25. The
findings not only highlighted that over 70% of youths are not
attaining their blood sugar target levels (measured by HbA1C), but
also that achieving target HbA1C is associated with a significantly
better quality of life (QoL) for young people (p<0.05).

The TEENs Study investigated factors associated with better blood
sugar control (defined as achieving target HbA1C levels recommended
by international organizations) and QoL per age class, with three
predefined age groups of 8-12, 13-18, and 19-25 years. The key
factors identified were a younger age (8 to 12 years), balanced
family support for diabetes management, and absence of family
financial burden related to diabetes. The TEENs Study findings will
help set a foundation for recommendations to enhance care aimed at
improving disease management and patient outcomes. The findings were
presented at the 74th Scientific Sessions of the American Diabetes
Association in San Francisco.

"The TEENs Study provides exceptional, contemporary data related
to the care and outcomes of young people with type 1 diabetes from
around the globe. In particular, the study aimed at identifying
modifiable barriers to diabetes management, especially during the
transition from pediatric to adult care, and is providing an
assessment of the challenges facing teens with type 1 diabetes and a
unique view of young adults," said Lori Laffel MD MPH, Associate
Professor/Chief of the Pediatric, Adolescent and Young Adult Section
of the Joslin Diabetes Center, Harvard Medical School, Boston, U.S.
and Co-Chair of the TEENs Registry Study Steering Committee. "The
findings from the TEENs Study can help us to design new approaches to
care that can overcome many of the challenges associated with
suboptimal glycemic control and psychosocial burdens of care in order
to help young people with type 1 diabetes and their families."

"Sanofi is committed to advancing knowledge in type 1 diabetes to
improve disease management and outcomes," said Pierre Chancel, Senior
Vice President, Global Diabetes, Sanofi. "Overall, insights from
TEENS give us a unique opportunity to better assess the unmet needs
of children, teens and young adults with type 1 diabetes, thereby
enhancing their glycemic control and quality of life as well as
limiting their risk of long-term complications."

Sanofi has partnered with more than 200 clinics, centers and
hospitals, notably with the T1D Exchange in the US, for interviewing
healthcare providers, youths with type 1 diabetes, and their families
in 20 countries (within Europe, the US, Latin America, Middle East,
North Africa, South Africa, India). The results showed that achieving
target HbA1C was associated with a significantly better QoL (p<0.05)
in a real life setting. The TEENs Study findings also showed that
over 70% of people aged 8 to 25 years were not achieving their HbA1C
target according to international guidelines, with only 32% of 8 to
12 year olds and 29% of 13 to 18 year olds (ISPAD guidelines), and
19% of 19 to 25 year olds (ADA guidelines) reaching HbA1C targets.

Furthermore, the TEENs findings suggest that young people with
type 1 diabetes can increase their chances of reaching their target
HbA1C levels and having a better QoL by modifying approaches to
diabetes management and education, such as using advanced intensive
insulin regimens, performing frequent blood sugar monitoring (more
than three times a day), engaging in regular exercise, and attending
to dietary management. Family support has also been identified as a
key factor influencing glycemic control (family involvement, absence
of diabetes-specific family conflicts), as well as maintaining
parental working activities, which was also linked to better QoL for
young people with type 1 diabetes. Absence of financial burden
related to diabetes was also associated with better glycemic control
and QoL for young people with type 1 diabetes.

The TEENs abstracts are titled:

1) Global Assessment of Factors Associated with Target Glycemic Control in
Youth with Type 1 Diabetes (T1D): the TEENs Study (Laffel et al. Oral presentation,
June 13, 6:00 pm PST, abstract # 32-OR)
2) Opportunities to Enhance Diabetes-specific Quality of Life (QoL) in Youth
with Type 1 Diabetes (T1D): the Global TEENs Study (Anderson et al. Oral presentation,
June 16, 9:00 am PST, abstract # 259-OR)
3) Diabetes-specific Health-related Quality of Life (QoL) in a Sample of US
Youth with Type 1 Diabetes (T1D) in the TEENs Study (Anderson et al. Poster
presentation, June 14, 11:30 am to 1:30 pm PST, abstract # 1247-P)

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi
has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new
Genzyme. Sanofi is listed in Paris and in New York .

Forward Looking Statements

Sanofi Forward Looking Statements

This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial results,
events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements
are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions.
Although Sanofi's management believes that the expectations reflected
in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject
to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could cause
actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential of
such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the
Group's ability to benefit from external growth opportunities, trends
in exchange rates and prevailing interest rates, the impact of cost
containment policies and subsequent changes thereto, the average
number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi,
including those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31, 2013. Other than as
required by applicable law, Sanofi does not undertake any obligation
to update or revise any forward-looking information or statements.

ots Originaltext: Sanofi Diabetes
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contacts: Media Relations: Jack Cox, Tel.: +(33)-1-53-77-46-46,
jack.cox@sanofi.com; Investor Relations: Sébastien Martel, Tel.:
+(33)-1-53-77-45-45, ir@sanofi.com; Global Diabetes Communications:
Tilmann
Kiessling, Mobile: +49-17-26-15-92-91, Tilmann.kiessling@sanofi.com.